Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report

AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.

argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.

The termination ends a cardiometabolic RNA-editing partnership that was paused for 12 months, closing out a deal under which Korro earned no milestone payments.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.

ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.

How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.

Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.